Skip to main content
Top
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

Lack of treatment-related mortality definitions in clinical trials of children, adolescents and young adults with lymphomas, solid tumors and brain tumors: a systematic review

Authors: Thai Hoa Tran, Michelle Lee, Sarah Alexander, Paul Gibson, Ute Bartels, Donna L Johnston, Carol Portwine, Marianna Silva, Jason D Pole, Lillian Sung

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

There is a lack of standardized definition for treatment-related mortality (TRM), which represents an important endpoint in cancer. Our objective was to describe TRM definitions used in studies of children, adolescents and young adults with lymphomas, solid tumors and brain tumors.

Methods

We conducted a systematic review of studies enrolling children, adolescents and young adults with lymphomas, solid tumors and brain tumors in which an anti-cancer intervention was randomized, or all study designs in which TRM was a primary or secondary outcome. We searched Ovid MEDLINE, EMBASE and Evidence-Based Medicine Reviews from 1980 to June 2013. Two reviewers evaluated study eligibility and abstracted data.

Results

In total, 67 studies were included and consisted of 62 randomized therapeutic trials and 5 TRM studies. None of the studies (0/67) provided a definition for TRM. Only one randomized trial of rhabdomyosarcoma provided a definition of early death.

Conclusions

We were unable to identify any TRM definitions used in studies of children, adolescents and young adults with lymphomas, solid tumors and brain tumors. Given that a proportion of this patient population may receive intensive treatment, there is an urgent need for consensus-based definitions of TRM for use across clinical trials.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ward E, Desantis C, Robbins A, Kohler B, Jemal A: Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin. 2014, 64 (2): 83-103. 10.3322/caac.21219.CrossRefPubMed Ward E, Desantis C, Robbins A, Kohler B, Jemal A: Childhood and adolescent cancer statistics, 2014. CA Cancer J Clin. 2014, 64 (2): 83-103. 10.3322/caac.21219.CrossRefPubMed
3.
go back to reference Kremer LC, Mulder RL, Oeffinger KC, Bhatia S, Landier W, Levitt G, Constine LS, Wallace WH, Caron HN, Armenian SH, Skinner R, Hudson MM, International Late Effects of Child- hood Cancer Guideline Harmonization Group: A worldwide collaboration to harmonize guidelines for the long-term follow-up of childhood and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Pediatr Blood Cancer. 2013, 60: 543-549. 10.1002/pbc.24445.CrossRefPubMed Kremer LC, Mulder RL, Oeffinger KC, Bhatia S, Landier W, Levitt G, Constine LS, Wallace WH, Caron HN, Armenian SH, Skinner R, Hudson MM, International Late Effects of Child- hood Cancer Guideline Harmonization Group: A worldwide collaboration to harmonize guidelines for the long-term follow-up of childhood and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Pediatr Blood Cancer. 2013, 60: 543-549. 10.1002/pbc.24445.CrossRefPubMed
4.
go back to reference Ethier MC, Blanco E, Lehrnbecher T, Sung L: Lack of clarity in the definition of treatment-related mortality: pediatric acute leukemia and adult acute promyelocytic leukemia as examples. Blood. 2011, 118 (19): 5080-5083. 10.1182/blood-2011-07-363333.CrossRefPubMed Ethier MC, Blanco E, Lehrnbecher T, Sung L: Lack of clarity in the definition of treatment-related mortality: pediatric acute leukemia and adult acute promyelocytic leukemia as examples. Blood. 2011, 118 (19): 5080-5083. 10.1182/blood-2011-07-363333.CrossRefPubMed
5.
go back to reference Moher D, Liberati A, Tetzlaff J, Altman DG: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009, 339: 332-336.CrossRef Moher D, Liberati A, Tetzlaff J, Altman DG: Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009, 339: 332-336.CrossRef
6.
go back to reference Crist W, Gehan EA, Ragab AH, Dickman PS, Donaldson SS, Fryer C, Hammond D, Hays DM, Herrmann J, Heyn R: The third intergroup Rhabdomyosarcoma Study. J Clin Oncol. 1995, 13 (3): 610-630.PubMed Crist W, Gehan EA, Ragab AH, Dickman PS, Donaldson SS, Fryer C, Hammond D, Hays DM, Herrmann J, Heyn R: The third intergroup Rhabdomyosarcoma Study. J Clin Oncol. 1995, 13 (3): 610-630.PubMed
7.
go back to reference Arico M, Ziino O, Valsecchi MG, Cazzaniga G, Baronci C, Messina C, Pession A, Santoro N, Basso G, Conter V: Acute lymphoblastic leukemia and Down syndrome: presenting features and treatment outcome in the experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP). Cancer. 2008, 113 (3): 515-521. 10.1002/cncr.23587.CrossRefPubMed Arico M, Ziino O, Valsecchi MG, Cazzaniga G, Baronci C, Messina C, Pession A, Santoro N, Basso G, Conter V: Acute lymphoblastic leukemia and Down syndrome: presenting features and treatment outcome in the experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP). Cancer. 2008, 113 (3): 515-521. 10.1002/cncr.23587.CrossRefPubMed
8.
go back to reference Bassal M, La MK, Whitlock JA, Sather HN, Heerema NA, Gaynon PS, Stork LC: Lymphoblast biology and outcome among children with Down syndrome and ALL treated on CCG-1952. Pediatr Blood Cancer. 2005, 44 (1): 21-28. 10.1002/pbc.20193.CrossRefPubMed Bassal M, La MK, Whitlock JA, Sather HN, Heerema NA, Gaynon PS, Stork LC: Lymphoblast biology and outcome among children with Down syndrome and ALL treated on CCG-1952. Pediatr Blood Cancer. 2005, 44 (1): 21-28. 10.1002/pbc.20193.CrossRefPubMed
9.
go back to reference Whitlock JA, Sather HN, Gaynon P, Robison LL, Wells RJ, Trigg M, Heerema NA, Bhatia S: Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children’s cancer group study. Blood. 2005, 106 (13): 4043-4049. 10.1182/blood-2003-10-3446.CrossRefPubMed Whitlock JA, Sather HN, Gaynon P, Robison LL, Wells RJ, Trigg M, Heerema NA, Bhatia S: Clinical characteristics and outcome of children with Down syndrome and acute lymphoblastic leukemia: a Children’s cancer group study. Blood. 2005, 106 (13): 4043-4049. 10.1182/blood-2003-10-3446.CrossRefPubMed
10.
go back to reference Maloney KW: Acute lymphoblastic leukaemia in children with Down syndrome: an updated review. Br J Haematol. 2013, 155 (4): 420-425.CrossRef Maloney KW: Acute lymphoblastic leukaemia in children with Down syndrome: an updated review. Br J Haematol. 2013, 155 (4): 420-425.CrossRef
11.
go back to reference Tran TH, Mitchell D, Dix D, Cellot S, Ethier MC, Gillmeister B, Hitzler J, Lewis V, Yanofsky R, Johnston DL, Portwine C, Price V, Zelcer S, Silva M, Michon B, Bowes L, Stobart K, Brossard J, Beyene J, Sung L: Infections in children with Down syndrome and acute myeloid leukemia: a report from the Canadian infections in AML research group. Infect Agent Cancer. 2013, 8 (1): 47-10.1186/1750-9378-8-47.CrossRefPubMedPubMedCentral Tran TH, Mitchell D, Dix D, Cellot S, Ethier MC, Gillmeister B, Hitzler J, Lewis V, Yanofsky R, Johnston DL, Portwine C, Price V, Zelcer S, Silva M, Michon B, Bowes L, Stobart K, Brossard J, Beyene J, Sung L: Infections in children with Down syndrome and acute myeloid leukemia: a report from the Canadian infections in AML research group. Infect Agent Cancer. 2013, 8 (1): 47-10.1186/1750-9378-8-47.CrossRefPubMedPubMedCentral
12.
go back to reference Zaky W, Dhall G, Ji L, Haley K, Allen J, Atlas M, Bertolone S, Cornelius A, Gardner S, Patel R, Pradhan K, Shen V, Thompson S, Torkildson J, Sposto R, Finlay JL: Intensive induction chemotherapy followed by myeloablative chemotherapy with autologous hematopoietic progenitor cell rescue for young children newly-diagnosed with central nervous system atypical teratoid/rhabdoid tumors: the Head Start III experience. Pediatr Blood Cancer. 2014, 61 (1): 95-101. 10.1002/pbc.24648.CrossRefPubMed Zaky W, Dhall G, Ji L, Haley K, Allen J, Atlas M, Bertolone S, Cornelius A, Gardner S, Patel R, Pradhan K, Shen V, Thompson S, Torkildson J, Sposto R, Finlay JL: Intensive induction chemotherapy followed by myeloablative chemotherapy with autologous hematopoietic progenitor cell rescue for young children newly-diagnosed with central nervous system atypical teratoid/rhabdoid tumors: the Head Start III experience. Pediatr Blood Cancer. 2014, 61 (1): 95-101. 10.1002/pbc.24648.CrossRefPubMed
Metadata
Title
Lack of treatment-related mortality definitions in clinical trials of children, adolescents and young adults with lymphomas, solid tumors and brain tumors: a systematic review
Authors
Thai Hoa Tran
Michelle Lee
Sarah Alexander
Paul Gibson
Ute Bartels
Donna L Johnston
Carol Portwine
Marianna Silva
Jason D Pole
Lillian Sung
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-612

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine